• About
  • Pipeline
  • Investor
  • News
  • Contact
  • About
  • Pipeline
  • Investor
  • News
  • Contact
  • Releases

    Q&A session – topline data from Study 0205

    Published: 4. January, 2024

    Link to release: (Link to Q&A session-image)

    Link to release: (Link to Q&A session-image)

    https://cessatech.com/wp-content/uploads/2024/01/QA-study-0205_video_LS.mp4

    Related articles

    Releases

    27. September, 2026

    EUSEM Press release: Nasal spray brings pain relief for children treated in the emergency department

    Paris, France: A treatment for pain, that is delivered via a nasal spray, offers...

    Read more

    Releases

    27. August, 2026

    CT001 ready for shipment to initial U.S. hospitals as launch activities commence

    Initial U.S. commercial supply of CT001 now available for shipment Launch activities initiated with...

    Read more

    Releases

    24. July, 2026

    Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu

    See also the updated Q&A documentation related to the Release: Link The European Medicines...

    Read more

    Stay up to date!

    Subscribe and get notified on Cessatech's latest news.
    An acceptance email will be sent to you, please check your spam.

    Almost there! Please check your inbox to confirm your subscription to Cessatech.

    Cessatech info
    • Cessatech A/S
      CVR: DK41293055
    • Strandvejen 60
    • DK-2900 Hellerup
    • +45 5352 2309
    • info@cessatech.com
    More information
    • About
    • Pipeline
    • Contact
    News
    • Releases
    • Facts
    • All